Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00959192|
Recruitment Status : Completed
First Posted : August 14, 2009
Results First Posted : January 1, 2016
Last Update Posted : January 1, 2016
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Biological: ACC-001 Other: QS-21||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2013|
Experimental: ACC-001 + QS-21
Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12Other: QS-21
IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
Placebo Comparator: QS-21
Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
- Incidence of Treatment-emergent Adverse Events (AEs) by Severity [ Time Frame: Baseline up to 24 months ]Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)
- Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data [ Time Frame: Baseline up to 24 months ]Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.
- Number of Participants With Abnormalities in Neurological Examination [ Time Frame: Baseline up to 24 months ]Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.
- Anti-a-beta IgG Titer at Specified Visits [ Time Frame: Baseline up to 24 months ]Geometric mean of anti-a-beta IgG titer from pre-study through Week 104
- Anti-a-beta IgM Titer at Specified Visits [ Time Frame: Baseline up to 24 months ]Geotmetric mean of anti-a-beta IgM titer from pre-study through Week 104
- The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 12, 26, 52, 78 and 104. [ Time Frame: Baseline up to 24 months ]The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11. Total score ranges from 0 to 70 points, with higher scores indicating a greater degree of impairment.
- The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 12, 26, 52,78 and 104. [ Time Frame: Baseline up to 24 months ]
The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living.
A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.
- The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 12, 26, 52 and 78. [ Time Frame: Baseline up to 24 months ]The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit - y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants' observed baseline scores in the study.
- The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 4, 8, 12, 16, 26, 30, 40, 52, 78 and 104. [ Time Frame: Baseline up to 24 months ]The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00959192
|Aichi, Japan, 451-8511|
|Ibaraki Prefectural Central Hospital|
|Ibaraki, Japan, 309-1793|
|Shonan Atsugi Hospital|
|Kanagawa, Japan, 243-8551|
|Kitasato University East Hospital|
|Kanagawa, Japan, 252-0380|
|Tazuke Kofukai Medical Research Institute Kitano Hospital|
|Osaka, Japan, 530-8480|
|The Jikei University School of medicine|
|Tokyo, Japan, 105-8471|
|Juntendo University Hospital|
|Tokyo, Japan, 113-8431|
|Juntendo Tokyo Koto Geriatric Medical Center|
|Tokyo, Japan, 136-0075|
|Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache|
|Tokyo, Japan, 158-8531|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|